PriceTargets.com logo

Roivant Sciences - ROIV Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $17.39
  • Forecasted Upside: 54.84%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$11.23 As of 10/7/2024 01:53 PM ET
▼ -0.15 (-1.32%)

This chart shows the closing price for ROIV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Roivant Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ROIV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ROIV

Analyst Price Target is $17.39
▲ +54.84% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is $17.39, with a high forecast of $23.00 and a low forecast of $12.50. The average price target represents a 54.84% upside from the last price of $11.23.

This chart shows the closing price for ROIV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Roivant Sciences. This rating has held steady since May 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/15/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/13/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/11/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/19/2024Cantor FitzgeraldReiterated RatingOverweight
9/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
9/11/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$12.00 ➝ $12.50
9/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
7/10/2024Piper SandlerBoost TargetOverweight ➝ Overweight$20.00 ➝ $22.00
6/18/2024Cantor FitzgeraldReiterated RatingOverweight
5/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00
4/3/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$16.00 ➝ $18.00
4/3/2024Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$14.00 ➝ $15.00
4/3/2024HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $18.00
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$23.00
2/15/2024Wolfe ResearchInitiated CoverageOutperform$17.00
2/14/2024HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $17.00
1/5/2024Piper SandlerInitiated CoverageOverweight$20.00
1/2/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$11.00 ➝ $12.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$14.00
11/15/2023GuggenheimLower TargetBuy ➝ Buy$17.00 ➝ $16.00
11/14/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$16.00 ➝ $15.00
10/17/2023GuggenheimInitiated CoverageBuy$17.00
9/27/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$14.00 ➝ $16.00
9/26/2023Truist FinancialReiterated RatingBuy ➝ Buy$23.00
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$15.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$15.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$15.00
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00
7/14/2023Truist FinancialReiterated RatingBuy ➝ Buy$23.00
7/14/2023JPMorgan Chase & Co.Boost Target$14.00 ➝ $16.00
6/29/2023HC WainwrightBoost Target$15.00 ➝ $18.00
6/23/2023Truist FinancialBoost Target$19.00 ➝ $23.00
6/23/2023Bank of AmericaBoost Target$10.50 ➝ $11.00
6/20/2023Cantor FitzgeraldReiterated RatingOverweight
6/8/2023Bank of AmericaInitiated CoverageNeutral$10.50
5/18/2023JPMorgan Chase & Co.Boost Target$12.00 ➝ $14.00
5/17/2023HC WainwrightBoost Target$14.00 ➝ $15.00
3/16/2023HC WainwrightReiterated RatingBuy$14.00
2/14/2023HC WainwrightReiterated RatingBuy$14.00
2/13/2023JPMorgan Chase & Co.Boost TargetOverweight$10.00 ➝ $11.00
1/19/2023The Goldman Sachs GroupBoost TargetBuy$10.00 ➝ $11.00
1/5/2023CitigroupBoost TargetBuy$11.00 ➝ $14.00
12/19/2022Leerink PartnersBoost TargetOutperform$8.00 ➝ $10.00
11/15/2022Leerink PartnersBoost TargetOutperform$7.00 ➝ $8.00
11/15/2022CitigroupBoost TargetBuy$10.00 ➝ $11.00
10/27/2022JPMorgan Chase & Co.Initiated CoverageOverweight$7.00
8/16/2022CitigroupBoost TargetBuy$9.00 ➝ $10.00
6/30/2022HC WainwrightReiterated RatingBuy$14.00
6/29/2022Leerink PartnersBoost TargetOutperform$6.00 ➝ $7.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$15.00 ➝ $12.00
5/23/2022Leerink PartnersInitiated CoverageOutperform$6.00
4/29/2022Cantor FitzgeraldInitiated CoverageOverweight$15.00
12/15/2021The Goldman Sachs GroupInitiated CoverageBuy$15.00
12/5/2021Leerink PartnersReiterated RatingBuy
11/8/2021HC WainwrightInitiated CoverageBuy$14.00
11/1/2021Leerink PartnersInitiated CoverageOutperform$11.00
10/27/2021CitigroupInitiated CoverageBuy$11.00
10/26/2021Truist FinancialInitiated CoverageBuy$15.00
10/26/2021Jefferies Financial GroupInitiated CoverageBuy$10.00
10/26/2021CowenInitiated CoverageOutperform
(Data available from 10/7/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 17 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2024
  • 15 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/10/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
6/9/2024
  • 10 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/9/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/8/2024
  • 7 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/7/2024
  • 26 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/7/2024

Current Sentiment

  • 26 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Roivant Sciences logo
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Read More

Today's Range

Now: $11.23
Low: $11.17
High: $11.42

50 Day Range

MA: $11.55
Low: $10.17
High: $12.50

52 Week Range

Now: $11.23
Low: $8.24
High: $13.06

Volume

1,709,722 shs

Average Volume

6,091,364 shs

Market Capitalization

$8.30 billion

P/E Ratio

2.22

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Roivant Sciences?

The following sell-side analysts have issued research reports on Roivant Sciences in the last twelve months: Bank of America Co., Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., and Wolfe Research.
View the latest analyst ratings for ROIV.

What is the current price target for Roivant Sciences?

9 Wall Street analysts have set twelve-month price targets for Roivant Sciences in the last year. Their average twelve-month price target is $17.39, suggesting a possible upside of 54.8%. Truist Financial Co. has the highest price target set, predicting ROIV will reach $23.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $12.50 for Roivant Sciences in the next year.
View the latest price targets for ROIV.

What is the current consensus analyst rating for Roivant Sciences?

Roivant Sciences currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ROIV.

What other companies compete with Roivant Sciences?

Other companies that are similar to Roivant Sciences include BioNTech, Moderna, BeiGene, Teva Pharmaceutical Industries and Genmab A/S. Learn More about companies similar to Roivant Sciences.

How do I contact Roivant Sciences' investor relations team?

Roivant Sciences' physical mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The company's listed phone number is 44-20-7400-3347 and its investor relations email address is [email protected]. The official website for Roivant Sciences is roivant.com. Learn More about contacing Roivant Sciences investor relations.